We are a leading company in the field of research and development of advanced therapies. Although we are a young company in the pharmaceutical industry, we have established a solid reputation for our commitment to quality and efficiency in the conduct of clinical trials.
In conclusion, Geistek Pharmaceuticals is a leading company in the field of drug research and development, with a highly qualified and experienced team and a commitment to ethics and transparency. For these reasons, Geistek is the best choice for conducting a clinical trial.
Throughout the development of a new drug, many entities participate with complementary value propositions and through collaborations that might establish very beneficial synergies for both institutions.
Geistek has agreements with more than 500 investment funds and private investors interested in advanced therapies. In addition, it currently works with a large volume of top-level biotechnological and pharmaceutical companies and research centres that carry out their activity in the design and development of this kind of therapies.
Due to the extensive networking that we have, we consider ourselves a key nexus to give the boost that biotechnological and pharmaceutical companies need in the development of their advanced therapies.
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment